"Macular Edema" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)
Descriptor ID |
D008269
|
MeSH Number(s) |
C11.768.585.439.245
|
Concept/Terms |
Irvine-Gass Syndrome- Irvine-Gass Syndrome
- Irvine Gass Syndrome
- Syndrome, Irvine-Gass
- Cystoid Macular Edema, Postoperative
Macular Edema, Cystoid- Macular Edema, Cystoid
- Edema, Cystoid Macular
- Cystoid Macular Dystrophy
- Macular Dystrophy, Dominant Cystoid
- Central Retinal Edema, Cystoid
- Cystoid Macular Edema
|
Below are MeSH descriptors whose meaning is more general than "Macular Edema".
Below are MeSH descriptors whose meaning is more specific than "Macular Edema".
This graph shows the total number of publications written about "Macular Edema" by people in this website by year, and whether "Macular Edema" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 26 | 3 | 29 |
2018 | 14 | 2 | 16 |
2019 | 8 | 1 | 9 |
2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Macular Edema" by people in Profiles.
-
OUTCOMES IN PATIENTS RESUMING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOLLOWING TREATMENT DELAY DURING THE CORONAVIRUS-19 PANDEMIC. Retina. 2021 12 01; 41(12):2456-2461.
-
The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown. Photodiagnosis Photodyn Ther. 2021 Sep; 35:102449.
-
Ophthalmology and COVID-19: The Impact of the Pandemic on Patient Care and Outcomes: An IRIS® Registry Study. Ophthalmology. 2021 12; 128(12):1782-1784.
-
IMPACT OF CORONAVIRUS DISEASE PANDEMIC ON INTRAVITREAL INJECTIONS TREATMENT FOR MACULAR DISEASES: Report From a Referral Hospital in Milan. Retina. 2021 04 01; 41(4):701-705.
-
Bilateral cystoid maculopathy as first manifestation of SARS-CoV-2 infection. J Fr Ophtalmol. 2021 May; 44(5):e249-e251.
-
Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study. PLoS One. 2021; 16(2):e0247161.
-
Intravitreal injections of anti-VEGF agents during COVID-19 pandemic: clinical audit from Tanta University Hospital. Int Ophthalmol. 2021 Apr; 41(4):1437-1443.
-
The Effect of Delay in Care among Patients Requiring Intravitreal Injections. Ophthalmol Retina. 2021 10; 5(10):975-980.
-
Central retinal vein occlusion with COVID-19 infection as the presumptive etiology. Indian J Ophthalmol. 2020 Nov; 68(11):2572-2574.
-
Intravitreal injections during COVID-19 outbreak: Real-world experience from an Italian tertiary referral center. Eur J Ophthalmol. 2021 Jan; 31(1):10-12.